Video Notes Flashcards: Autonomic Nervous System & Related Topics
Sympathetic and Parasympathetic Organization
Autonomic nervous system (ANS) consists of two divisions: Sympathetic (SNS) and Parasympathetic (PSNS).
SNS: Thoracolumbar outflow (preganglionic neurons originate from intermediolateral cell column, IML, at T1–L2).
PSNS: Craniosacral outflow (preganglionic neurons originate from CN III, VII, IX, X and S2–S4).
Ganglia locations:
SNS: ganglia near spinal cord (sympathetic chain); postganglionic neurons typically release norepinephrine (NE).
PSNS: ganglia near or within target organs; postganglionic neurons release acetylcholine (ACh).
Neurotransmitters:
Pre‑ganglionic: ACh (nicotinic Nn).
SNS postganglionic: NE (adrenergic).
PSNS postganglionic: ACh (muscarinic).
Organ effects summary (parasympathetic vs sympathetic):
Heart: SNS β1 ↑HR/contractility; PSNS M2 ↓HR/contractility.
Lungs: SNS β2 bronchodilation; PSNS M3 bronchoconstriction.
Eye: SNS α1 mydriasis; PSNS M3 miosis.
GI: SNS ↓ motility/secretions; PSNS ↑ motility/secretions.
Bladder: SNS relaxes detrusor, contracts sphincter; PSNS contracts detrusor, relaxes sphincter.
Sweat glands: SNS often via sympathetic cholinergic (M3); PSNS minimal direct effect.
Key high‑yield integration: receptor types dictate physiologic responses across organ systems.
Sympathetic Preganglionic Neurons and Ramus Anatomy
Origin: intermediolateral cell column (IML) from T1 to L2; limits sympathetic outflow to thoracolumbar region -> “thoracolumbar outflow.”
White rami communicantes: myelinated preganglionic fibers; located only T1–L2; connect spinal nerves to sympathetic chain ganglia.
Gray rami communicantes: unmyelinated postganglionic fibers; located at all spinal levels; allow postganglionic fibers to rejoin spinal nerves and reach structures via skin, sweat glands, arrector pili, blood vessels.
Function: entry of preganglionic fibers into the sympathetic chain and distribution to target organs.
Horner Syndrome: Superior Cervical Ganglion Lesion Clinical Signs
Horner syndrome = disruption of sympathetic supply to face/eye; parasympathetic system not involved.
Classic triad (PAM): Ptosis, Anhidrosis, Miosis (with optional Enophthalmos).
Lesion locations/causes include brainstem, T1 level, or superior cervical ganglion; classic association with Pancoast tumor compressing the T1 root.
Cocaine test blocks NE reuptake (no dilation) and hydroxyamphetamine helps localize lesion.
Pathway to the Eye and Face (Three-Neuron Arc)
1) First-order neuron (central): start in hypothalamus → descend brainstem/spinal cord to T1.
2) Second-order neuron (preganglionic): exits spinal cord at T1 → ascends in sympathetic chain to superior cervical ganglion.
3) Third-order neuron (postganglionic): begins at superior cervical ganglion → follows carotid artery branches to eye, eyelids, sweat glands, and facial vasculature.
Parasympathetic Pathway to Lacrimal Gland
Goal: lacrimal gland tear production; PSNS promotes secretions.
Preganglionic origin: facial nerve (CN VII); specifically greater petrosal nerve carries parasympathetic fibers.
Pathway assembly: greater petrosal joins deep petrosal nerve → forms nerve of the pterygoid canal (Vidian nerve).
Synapse: preganglionic fibers synapse in the pterygopalatine ganglion (relay station).
Postganglionic path to lacrimal gland:
Hitchhike on branches of trigeminal nerve: first V2 (maxillary) then V1 (ophthalmic) via zygomatic nerve, finally reaching lacrimal nerve (branch of V1).
Outcome: stimulation of tear secretion by lacrimal gland.
Autonomic Toxidromes: Antimuscarinic, Cholinergic, Nicotinic
Antimuscarinic toxidrome (muscarinic blockade):
Causes: atropine, diphenhydramine, TCAs, antipsychotics, benztropine, etc.
Classic features: Dry (no sweating/saliva), Hot (hyperthermia), Blind (mydriasis/blurred vision), Red (flushed skin), Mad (delirium).
Other signs: urinary retention, constipation, tachycardia.
Cholinergic toxidrome (muscarinic excess):
Causes: organophosphates, carbamates, AChE inhibitors (donepezil, physostigmine).
Classic features (DUMBBELSS): Diarrhea, Urination, Miosis, Bronchorrhea, Emesis, Lacrimation, Salivation, Sweating, Sludge (bronchial secretions).
Nicotinic toxidrome (nicotinic overactivation):
Causes: organophosphates (nicotinic component), nicotine, succinylcholine.
Features: neuromuscular fasciculations/cramps → weakness, paralysis; autonomic effects (hypertension, tachycardia);
Note: secretions are muscarinic-dominant; nicotinic effects may not include secretions.
Vasovagal Syncope: Reflex Physiology
Vasovagal event: common cause of syncope due to abrupt autonomic shift.
Mechanism: ↑ parasympathetic (via vagus nerve) and ↓ sympathetic activity → bradycardia and vasodilation with hypotension; reduced cerebral perfusion leads to syncope.
Common triggers: emotional stress, prolonged standing, heat exposure, medical procedures, anxiety.
Reflex arc:
Trigger → brainstem autonomic centers misinterpret stress as requiring parasympathetic activation.
Parasympathetic surge (vagus) → bradycardia.
Sympathetic withdrawal → vasodilation, decreased SVR.
Net effect: ↓ CO and arterial pressure → transient loss of consciousness; rapid recovery when lying flat.
Clinical features: prodrome (nausea, dizziness, sweating), pale/cool skin, brief loss of consciousness, quick recovery due to restored venous return.
M3 Muscarinic Receptors: Tissue Responses
M3 receptor basics:
Type: Gq-coupled; located on smooth muscle, glands, endothelial cells.
Activation → ↑ IP3/DAG → ↑ intracellular Ca2+.
Core effect: “Wet and constricted.”
Tissue effects:
Eye: pupillary sphincter → contraction (miosis); ciliary muscle → accommodation.
Glands: salivary, lacrimal → secretions; sweat glands → sweating (sympathetic cholinergic, still via M3).
Lungs: bronchial smooth muscle constriction; bronchial glands ↑ mucus.
GI tract: increased motility and secretions.
Bladder: detrusor contraction; internal sphincter relaxation → easier voiding.
Blood vessels: endothelial M3 → NO release → vasodilation and BP decrease (indirect effect).
ACh-Induced Vascular Responses: Endothelium-Dependent vs Independent
Normal endothelium intact: ACh binds endothelial M3 → eNOS activation → NO production → smooth muscle relaxation → vasodilation (↓BP).
Damaged/denuded endothelium: no endothelial NO; ACh acts directly on vascular smooth muscle M3 → Ca2+ increase → contraction → vasoconstriction.
Clinical note: ACh can cause paradoxical vasospasm in diseased vessels with denuded endothelium.
α1 Receptor Pharmacology: Agonists and Blockade
α1 receptors on vascular smooth muscle (arterioles, venous smooth muscle): Gq → ↑ IP3/DAG → ↑ Ca2+ → contraction → vasoconstriction.
α1 agonists:
Examples: Phenylephrine, norepinephrine (α1 component), midodrine.
Effects: ↑ PVR, ↑ venous tone, ↑ BP.
Reflex effect: baroreceptors trigger parasympathetic activity → reflex bradycardia.
α1 blockade:
Drugs: Prazosin, doxazosin, phenoxybenzamine, phentolamine.
Effects: vasodilation, ↓ BP; venodilation → ↓ venous return → orthostatic hypotension.
Reflex effect: baroreceptors trigger sympathetic activation → reflex tachycardia.
Presynaptic α2 Autoreceptors and Yohimbine Reversal
Presynaptic α2 autoreceptors: brake on NE release from sympathetic nerve endings.
Mechanism: NE binds α2 → Gi activation → ↓ cAMP → ↓ Ca2+ entry → less NE release.
α2 agonists (e.g., clonidine) strengthen brake → less NE → weaker NE effects on α1.
Yohimbine: α2 antagonist → blocks the brake → increases NE release.
Outcome in vas deferens: more NE → more α1 contraction; Yohimbine reverses α2 brake to restore contraction.
β2 Receptors and Airway Smooth Muscle; β-Blocker Antagonism
β2 receptor basics: Gs → ↑ cAMP → PKA activation → ↓ intracellular Ca2+ → smooth muscle relaxation.
β2 agonists (e.g., albuterol, salmeterol, terbutaline, formoterol): bronchodilation; used in asthma/COPD; SABA for rescue, LABA for maintenance with inhaled corticosteroids.
β-blocker antagonism: nonselective blockers (e.g., propranolol, nadolol, timolol) block β2 → risk of bronchoconstriction in asthma/COPD; β1-selective blockers (metoprolol, atenolol, bisoprolol) are safer but at higher doses may lose selectivity.
Dale’s Vasomotor Reversal (Epinephrine after α-Blockade)
Normal epinephrine action: binds α1 (vasoconstriction) and β2 (vasodilation); net effect depends on dose/location; often ↑ systolic BP with slight diastolic dip due to β2 effects.
After irreversible α-blockade (e.g., phenoxybenzamine): α1 vasoconstriction blocked; β2 vasodilation remains unopposed.
Epinephrine administration in this state causes a fall in BP due to unopposed β2-mediated vasodilation: Dale’s vasomotor reversal.
Clinical relevance: explains paradoxical BP drop after epinephrine in patients on α-blockers (pheochromocytoma management, MAOIs, etc.).
Low-Dose Epinephrine Hemodynamics
At low dose, β effects dominate over α effects.
Receptor effects:
β1 (heart): ↑ SA node firing → ↑ HR; ↑ contractility → ↑ systolic BP.
β2 (skeletal muscle vasculature): Vasodilation → ↓ diastolic BP.
Hemodynamic pattern:
Systolic BP up; Diastolic BP down; Pulse pressure widened; HR up.
MAP may be unchanged or slightly increased; reflexes may be blunted due to vasodilation in some beds.
Norepinephrine Hemodynamics (α1 + β1 dominant, β2 weak)
Receptor selectivity: strong α1 vasoconstriction; strong β1 increases inotropy/chronotropy; β2 minimal.
Hemodynamics:
Systolic BP rises (β1-driven ↑ contractility) and diastolic BP rises (α1 vasoconstriction).
MAP rises significantly; reflex bradycardia occurs due to baroreceptor activation given high BP.
MAOI–Tyramine Hypertensive Crisis: Phentolamine for Management
Tyramine in foods (aged cheese, red wine, cured meats) is normally degraded by MAO; with MAOI, tyramine enters sympathetic nerve endings and releases large NE leading to hypertensive crisis.
Treatment: IV phentolamine (nonselective, reversible α1/α2 blocker) induces vasodilation to rapidly lower BP.
Clinical contexts: pheochromocytoma, cocaine-induced hypertension as well.
Labetalol for Rapid IV Blood Pressure Control in Pregnancy
Clinical problem: pregnant patient with severe HTN (preeclampsia/eclampsia).
Labetalol properties: mixed α1 and β receptor blockade.
α1 blockade → vasodilation → ↓ systemic vascular resistance.
β1 blockade → slows heart rate and reduces contractility → ↓ cardiac output.
Advantage: rapid BP reduction without reflex tachycardia due to β-blockade dampening the reflex.
Alternative safe options in pregnancy include hydralazine, methyldopa, nifedipine; avoid ACE inhibitors/ARBs.
Master Study Guide: Integrative Concepts for ANS & Pharmacology
Adrenergic receptors functions:
α1: vasoconstriction; SNA tone; vascular smooth muscle.
α2: presynaptic inhibition of NE release; feedback control.
β1: heart (inotropy/chronotropy); kidney renin release.
β2: bronchodilation, vasodilation in skeletal muscle, uterine relaxation.
β3: lipolysis, bladder relaxation (not heavily emphasized in this deck).
GPCR signaling types:
Gs: ↑ cAMP (β receptors, certain dopaminergic receptors).
Gi: ↓ cAMP (α2, some M2 receptors).
Gq: ↑ IP3/DAG → Ca2+ signaling (α1, M3, H1, V1).
Signaling pathways: GPCRs, RTKs (e.g., insulin receptor), JAK/STAT, serine/threonine kinases; intracellular receptors (steroids).
Direct vs indirect sympathomimetics; indirect agents increase NE release or inhibit reuptake.
Catecholamine synthesis and breakdown: Tyrosine → DOPA → Dopamine → NE → Epi; MAO/COMT metabolize catecholamines to VMA.
Reflexes: α1 agonists trigger reflex bradycardia; β2 agonists trigger reflex tachycardia; ganglion blockers abolish reflexes.
Pregnancy-associated hypertension management: Labetalol; alternative safe drugs include hydralazine, methyldopa, nifedipine.
Poisoning management: Atropine for antimuscarinic/cholinergic toxidromes; pralidoxime for cholinesterase inhibitors; phentolamine for MAOI–tyramine crises.
Tests for Horner localization: cocaine vs hydroxyamphetamine; Pancoast tumor association with T1 root.
Tissue Bases: Extracellular Matrix (ECM) and Basal Lamina
ECM components and roles:
Collagen: provides strength; key amino acids Glycine every third residue; Proline/hydroxyproline promote helix; Vitamin C needed for collagen hydroxylation; disulfide bonds stabilize triple helix.
Elastin: provides elasticity; rich in proline/glycine; cross-linking.
Proteoglycans: hydrated, resist compression; GAGs covalently linked to core proteins; Hyaluronan forms backbone of proteoglycan matrices; strong for joint lubrication.
Fibrillin: essential for elastic fiber assembly; Marfan syndrome via fibrillin mutations.
Basal lamina: structural support and selective barrier; laminin anchors epithelia; heparan sulfate proteoglycans (HSPGs) regulate filtration and growth; in hyperglycemia, HSPGs degrade affecting renal filtration.
Tissue defects: collagen and ECM mutations/diseases (OI, EDS, Alport, Goodpasture, EB types) produce systemic connective tissue problems.
Collagenopathies and Related Connective Tissue Disorders (Summary)
Osteogenesis imperfecta: type I collagen gene mutations; bone fragility.
Ehlers-Danlos syndrome: defective collagen types I, III, V; hyperextensible joints; fragile skin.
Alport syndrome: type IV collagen mutation; nephritis and hearing loss.
Goodpasture syndrome: autoantibodies against type IV collagen; renal and pulmonary basement membrane injury.
Epidermolysis bullosa: keratin or laminin/integrin defects; skin fragility.
Dystrophic EB: collagen VII defect; skin and mucosal fragility.
Marfan syndrome (fibrillin defect): aortic root dilation and ocular issues.
Cell Interactions and Adhesion Molecules
Fibronectin: stabilizes cell adhesion to ECM; guides cell shape, growth direction, migration, wound healing.
Integrins: mediate focal adhesion; bind to actin stress fibers; signal transduction.
Hemidesmosomes: integrins binding to intermediate filaments.
Cadherins: cell-cell adhesion via actin cytoskeleton (catenins).
Bullous pemphigoid: autoantibodies to hemidesmosomes; pemphigus vulgaris: desmosomal defects.
RAC and RHO: small GTPases control cytoskeletal rearrangements and focal adhesions during cell movement.
Signal Transduction: Key Pathways Overview
Intracellular signaling proteins:
Kinases, GTPases.
Cell surface receptors:
GPCRs, receptor tyrosine kinases (e.g., Ras-MAPK), serine/threonine kinases, JAK/STAT, ion-channel linked receptors.
GPCR signaling schemes:
Gs → ↑ cAMP → PKA activation.
Gi → ↓ cAMP.
Gq → ↑ IP3/DAG → ↑ Ca2+.
Bacterial toxins and signaling:
Cholera toxin: locks Gs in active state (↑ cAMP).
Pertussis toxin: locks Gi in inactive state (↑ cAMP).
RTK pathway (Ras-MAPK): Grb2 -> SOS -> Ras activation -> MAPK cascade.
Steroid hormone signaling: nuclear receptors (estrogen, progesterone, glucocorticoids).
pH, Acids, and Buffering: Henderson–Hasselbalch and Acid–Base Disorders
Henderson–Hasselbalch equation:
Acids vs bases terminology; pKa defines strength; smaller pKa = stronger acid.
Acidemia vs alkalemia: arterial pH thresholds: acidemia < 7.35; alkalemia > 7.45.
Metabolic vs respiratory disorders:
Metabolic acidosis/alkalosis: low/high HCO3−; compensatory changes in PCO2 via respiration.
Respiratory acidosis/alkalosis: abnormal PCO2; renal/metabolic compensation.
Notable patterns:
Anion gap calculations (not explicitly listed, but implied in metabolic acidosis workup).
Glycolysis, Pyruvate, and TCA Cycle: Core Metabolism Essentials
Glycolysis overview (key steps and control points):
Step 1: Glucose → glucose-6-phosphate (hexokinase); irreversible; consumes 1 ATP (rate-limiting).
Step 3: Fructose-6-phosphate → fructose-1,6-bisphosphate (PFK-1); irreversible; consumes 1 ATP (rate-limiting).
Step 6: G3P → 1,3-BPG (G3PD); generates 2 NADH.
Step 7: 1,3-BPG → 3-PG (phosphoglycerate kinase); substrate-level phosphorylation; yields 2 ATP.
Step 10: PEP → pyruvate (pyruvate kinase); substrate-level phosphorylation; yields 2 ATP.
Shuttle systems: glycerol-3-phosphate shuttle (brain, skeletal muscle) yields ~30 ATP; malate-aspartate shuttle yields ~32 ATP.
Pyruvate fate decisions:
Pyruvate → acetyl-CoA via pyruvate dehydrogenase (PDH) complex; links glycolysis to TCA; regulated by NAD+/NADH, acetyl-CoA, Ca2+, and vitamin cofactors (B1, B2, B3, B5).
Pyruvate can convert to lactate (lactate dehydrogenase), oxaloacetate (pyruvate carboxylase), alanine (alanine transaminase), ethanol (in microbes).
Pyruvate dehydrogenase complex (PDH): requires thiamine (B1, TPP), lipoate, FAD, NAD+, CoA; active with insulin, NAD+, CoA, Ca2+; inhibited by acetyl-CoA, NADH, ATP, high cAMP, arsenic; deficiency causes lactic acidosis and neurodevelopmental issues.
TCA cycle highlights (rate-limiting steps and key enzymes):
Isocitrate → α-ketoglutarate: isocitrate dehydrogenase (rate-limiting, produces NADH).
α-KG → succinyl-CoA: α-ketoglutarate dehydrogenase complex (produces NADH).
Succinyl-CoA → succinate: succinyl-CoA synthetase (GDP → GTP).
Succinate → fumarate: succinate dehydrogenase (complex II; produces FADH2).
Malate → oxaloacetate: malate dehydrogenase (produces NADH).
TCA inhibitors and irreversible steps listed (e.g., citrate synthase, isocitrate dehydrogenase, α-KG dehydrogenase).
ETC overview: oxidative phosphorylation drives ~90% of ATP; substrate-level phosphorylation in cytosol ~10%.
Clinical notes: hypoxia → lactic acidosis; statins impact CoQ and mitochondrial function; cytochrome c release → apoptosis; various inhibitors affect complexes I–IV.
Glycogen Storage Diseases: Overview and Examples
Glycogen storage disorders involve abnormal glycogen metabolism.
Key diseases and enzyme defects:
Von Gierke disease: glucose-6-phosphatase deficiency; severe hypoglycemia, hepatomegaly, lactic acidosis.
Pompe disease: acid maltase (alpha-1,4-glucosidase) deficiency; cardiomegaly and muscle weakness.
Cori disease (debranching enzyme deficiency): milder hypoglycemia, hepatomegaly.
Andersen disease (branching enzyme deficiency): infantile hypotonia, cardiomyopathy, cirrhosis.
McArdle disease (muscle glycogen phosphorylase deficiency): muscle cramps with exercise, myoglobinuria.
Hers disease (liver glycogen phosphorylase deficiency): hypoglycemia, hepatomegaly.
Mnemonic: “PAM does not have hypoglycemia” (per page 28-29) as a study cue.
Gluconeogenesis: Substrates, Pathways, and Control
Substrates: lactate, glucogenic amino acids, glycerol, odd-chain fatty acids.
Cori cycle: lactate ↔ glucose cycling between peripheral tissues and liver.
Cahill cycle: alanine ↔ glucose cycling between liver and muscle.
Key steps:
Pyruvate → oxaloacetate → phosphoenolpyruvate (PEP) via pyruvate carboxylase (requires biotin + CO2) and PEP carboxykinase (PEPCK) (uses 1 ATP and 1 GTP respectively).
Fructose-1,6-bisphosphate → fructose-6-phosphate via FBPase-1 (rate-limiting step).
Glucose-6-phosphate → glucose via glucose-6-phosphatase.
Regulation:
Pyruvate carboxylase activated by acetyl-CoA; inhibited by ADP.
PEPCK regulated by glucagon, epinephrine, cortisol; inhibited by insulin.
FBPase-2 activity and F2,6BP levels regulate PFK-1 and gluconeogenesis (low F26BP favors gluconeogenesis; high F26BP favors glycolysis).
Pyruvate carboxylase deficiency leads to reduced OAA, impaired TCA and gluconeogenesis, shunting to lactate; treatment with biotin.
HMP Shunt (Pentose Phosphate Pathway)
Generates NADPH (oxidative branch) and ribose-5-phosphate for nucleotide synthesis (non-oxidative branch can interconvert sugars).
Key enzymes: G6PD (rate-limiting in oxidative phase); transketolase (requires TPP/B1); transaldolase (non-oxidative).
NADPH is required for reductive biosynthesis and glutathione reduction (antioxidant defense).
Clinical correlations:
G6PD deficiency → susceptibility to oxidative stress; Heinz bodies; hemolysis.
Chronic granulomatous disease arises from NADPH oxidase defects, impairing microbial killing.
Malaria/antimalarial drugs can affect NADPH and oxidative stress pathways.
Metabolic and Immune System Sections (Overview)
Essential immune components:
Chemokines attract cells to tissues via chemokine receptors.
Cytokines (e.g., IL-3, GM-CSF, G-CSF, M-CSF, IL-5) promote proliferation and differentiation of immune lineages.
Primary lymphoid tissues: bone marrow and thymus; secondary lymphoid tissues include spleen, lymph nodes, tonsils, adenoids, appendix, Peyer’s patches; mucosal-associated lymphoid tissue.
Innate immunity: alternative pathway of complement via C3b deposition.
Adaptive immunity: complement classical pathway activated by antibody binding.
Basic inflammatory and immune signaling (brief): chemokines and cytokines guide immune cell traffic and activation; GPCR, RTK, JAK/STAT signaling underlie many immune responses.
Pharmacodynamics: Basic Concepts and Receptor Pharmacology
Pharmacodynamics = what the drug does to the body; dose–response relationships, receptor interactions, and downstream effects.
Key terms:
Agonist: activates receptor.
Pharmacologic antagonist: binds receptor and blocks activation.
Physiologic antagonist: binds different receptor to oppose effect.
Chemical antagonist: binds to agonist, reducing effect.
Constitutive activity: receptor activity in absence of ligand.
Inverse agonist: stabilizes inactive receptor state; reduces constitutive activity.
Receptor types:
Ion-channel receptors (ligand-gated channels).
GPCRs (G-protein-coupled receptors).
Enzyme-linked receptors (e.g., receptor tyrosine kinases).
Intracellular receptors (nuclear receptors).
GPCR signaling families (illustrative):
Gs → increases cAMP → activates PKA.
Gi → decreases cAMP.
Gq → increases IP3 and DAG → increases Ca2+.
G12/13 → Rho family signaling.
Desensitization and tolerance:
Downregulation: receptor internalization/degradation.
Tachyphylaxis: receptor phosphorylation leading to reduced responsiveness.
Upregulation: increased receptor number due to antagonist or absence of agonist.
Pharmacokinetics interplay (brief): pharmacokinetics informs pharmacodynamics via drug exposure, but see dedicated PK section.
Pharmacokinetics: Absorption, Distribution, Metabolism, Excretion (ADME)
Ionization and absorption:
Nonionized (lipid-soluble) drugs cross membranes easily; ionized (water-soluble) do not.
pH partitioning and pKa determine ionization state; ion trapping manipulates excretion.
Acidic drugs trapped in basic urine; basic drugs trapped in acidic urine (clinical poison management).
Bioavailability (F): fraction of an administered dose reaching systemic circulation.
For IV administration, F = 1.
F = f × (1 − ER); ER = extraction ratio = CL_liver / Q.
Bioequivalence: two products with equivalent rate and extent of absorption.
First-pass effect: hepatic and gut wall metabolism before reaching systemic circulation; routes to bypass include sublingual, rectal, and transdermal.
Absorption parameters:
Cmax, Tmax describe rate and extent of absorption.
Volume of distribution (Vd): distribution of a drug between plasma and body compartments.
Vd = (amount of drug in the body) / (plasma drug concentration).
Typical values/interpretation:
Vd < 4 L: mostly confined to blood/plasma.
~14 L: distributed between plasma and interstitial fluid.
Vd > 42 L: wide distribution into tissues; long half-life potential.
Clearance (CL): rate of elimination relative to plasma concentration.
CL = (rate of elimination) / (plasma concentration).
First-order kinetics: clearance constant; elimination proportional to concentration; most drugs follow this.
Zero-order kinetics: elimination rate is constant irrespective of concentration (e.g., aspirin at high doses, alcohol, phenytoin).
Half-life (t1/2): time for plasma concentration to fall by half.
Steady-state concentration (Css) is achieved after ~5 half-lives; Css proportional to dose and inversely proportional to clearance.
where t is dosing interval.
Loading dose concept:
Loading dose = Vd × C_target (variant shown as Vd × Tc in some notes), used to rapidly achieve therapeutic concentration.
Drug–protein binding: competition for albumin can displace drugs, increasing free (active) drug fraction.
P-glycoprotein and CYP interactions:
Inducers: rifampin, St. John’s wort; inhibit or induce hepatic metabolism and may alter drug levels.
Inhibitors: grapefruits, amiodarone, cimetidine, ciprofloxacin, ritonavir; can raise levels of coadministered drugs.
First-pass vs alternative routes summary:
Sublingual and transdermal routes avoid first-pass metabolism; rectal offers partial bypass.
Pharmacokinetics: Special Concepts and Calculations
Volume of distribution notes:
Small Vd indicates confinement to plasma; large Vd indicates tissue distribution.
Loading dose rationale and calculation notes.
Bioavailability and extraction ratio concepts, including liver extraction considerations.
First-pass effect and strategies to bypass it.
Drug interactions due to transporter (P-gp) and CYP enzyme modulation.
Clinical Highlights: High‑Yield Integrations and Mnemonics
Adrenergic receptor summary:
α1 squeezes vessels (vasoconstriction);
α2 brakes NE release;
β1 heart and kidney (β1 ↑HR/contractility; renin);
β2 lungs, skeletal muscle vasodilation, uterine relaxation.
GPCR signaling fundamentals: Gs (cAMP), Gi (↓ cAMP), Gq (Ca2+ via IP3/DAG).
Contrast of epinephrine vs norepinephrine patterns in hemodynamics and reflexes (α vs β effects).
Hormonal regulation basics: insulin and glucagon balance metabolic pathways in liver and peripheral tissues.
Common drug safety concepts: therapeutic index, therapeutic window, efficacy, potency, and spare receptors.
Pregnancy pharmacology: select antihypertensives that are safer in pregnancy (labetalol, hydralazine, methyldopa, nifedipine).
Appendix: Enzyme Cofactors, Vitamins, and Deficiencies (Biochem Reference)
Key vitamins and coenzymes:
B1 (thiamine, TPP): PDH, branched-chain dehydrogenases; Beriberi (wet/dry); Wernicke-Korsakoff.
B2 (riboflavin, FAD/FMN): redox reactions.
B3 (niacin, NAD+/NADP+): redox reactions.
B5 (pantothenic acid): CoA formation.
B6 (pyridoxine, PLP): transaminases.
B7 (biotin): carboxylases.
B9 (folate): thymidylate synthesis; THF.
B12 (cobalamin): methylation and odd-chain metabolism.
Clinically relevant metabolic disorders appear in the context of deficiencies and genetic defects (e.g., PKU, homocystinuria, glycogen storage diseases, porphyrias, urea cycle defects).
References to Equations and Quantitative Concepts (Summary)
Henderson–Hasselbalch (acid–base and ion trapping):
Weak acid: Ionization increases with pH; weak base: ionization increases with lower pH.
Pharmacokinetics:
Bioavailability:
ER (extraction ratio):
Clearance:
Volume of distribution:
Half-life:
Steady-state concentration: approximately after
Maintenance dose:
Loading dose: (some sources use target concentration, noted as Tc/Css)
pH/pKa ion trapping conventions:
Acidic drugs become more ionized in basic environments; basic drugs become more ionized in acidic environments.
Practical clinical note: adjust urine pH to enhance excretion of toxicants via ion trapping.
Quick-Reference: Key Topics by Page (Condensed Mapping)
Page 1–2: Sympathetic preganglionic origin (T1–L2), white/gray rami anatomy, thoracolumbar outflow.
Page 3–5: Horner syndrome pathophysiology, signs, lesion levels, diagnostic tests.
Page 6–7: Parasympathetic lacrimal pathway, pterygopalatine ganglion, trigeminal hitchhike.
Page 8–9: Toxidromes—antimuscarinic, cholinergic, nicotinic.
Page 10–11: Vasovagal reflex physiology and clinical features.
Page 12–13: M3 receptor tissue effects; endothelium NO mechanism with intact vs denuded endothelium.
Page 14–15: α1 receptor pharmacology (agonists vs blockers) and reflexes.
Page 16–17: Presynaptic α2 autoreceptors, clonidine effect, yohimbine reversal.
Page 18–19: β2 receptor agonists for airway; β-blocker implications.
Page 20–21: Dale’s vasomotor reversal; clinical relevance.
Page 22–25: Low-dose epinephrine vs norepinephrine hemodynamics; pregnancy safety and crisis management.
Page 26–29: Master study guide integrative points; horner localization cues; lacrimal pathway recapped; vasovagal syncope recap.
Page 30–33: ECM components, basal lamina, laminin, proteoglycans; cell junctions; signaling basics.
Page 34–36: Diffusion basics; pH and enzymes; pharmacodynamics overview.
Page 37–41: Carbohydrate metabolism and transport; pyruvate fate; PDH and deficiency notes; vitamin deficiencies.
Page 42–46: TCA cycle and inhibitors; PPP; glycogen disorders; gluconeogenesis.
Page 47–53: Non-glucose sugar metabolism; lysosomal storage diseases; urea cycle disorders; amino acid metabolism.
Page 53–60: Immune system basics; pharmacodynamics; pharmacokinetics fundamentals.
Page 61–67: Ion trapping, bioavailability, first-pass effect; metabolism (CYPs, UGTs, GSTs, SULTs, NATs); PK concepts; half-life and steady state.